| 1354 |
National Cancer Institute |
Html |
null |
Melanoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of melanoma. |
|
|
CLICK HERE |
| 1465 |
National Cancer Institute |
Html |
en |
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders. |
| cytogenetically normal AML | 0.472151 |
| acute myelogenous leukemia | 0.566998 |
| acute myeloid leukemias | 0.479592 |
| acute leukemia cells | 0.490369 |
| Mixed-phenotype acute leukemia | 0.492893 |
| pediatric AML chromosomal | 0.458451 |
| acute leukemias | 0.458907 |
| mutations | 0.522652 |
| myeloid leukemia patients | 0.500607 |
| leukemia group | 0.471134 |
| biphenotypic acute leukemia | 0.49298 |
| children | 0.465 |
| pediatric myeloid leukemia | 0.49349 |
| childhood AML | 0.456416 |
| chronic myelomonocytic leukemia | 0.469481 |
| AML | 0.543947 |
| World Health Organization | 0.492048 |
| CEBPA mutations | 0.477251 |
| leukemia development | 0.468848 |
| acute monocytic leukemia | 0.483805 |
| chronic myelogenous leukemia | 0.468404 |
| Acute myelomonocytic leukemia | 0.489711 |
| prognostic significance | 0.496134 |
| international retrospective study | 0.454979 |
| promyelocytic leukemia cases | 0.462082 |
|
| pediatric leukemia | 0.454781 |
| pediatric AML patients | 0.456596 |
| et al. | 0.655126 |
| acute megakaryoblastic leukemia | 0.509773 |
| normal pediatric AML | 0.45551 |
| myeloid neoplasms | 0.47963 |
| internal tandem duplication | 0.460861 |
| Br J Haematol | 0.501425 |
| acute promyelocytic leukaemia | 0.457345 |
| normal myeloid development | 0.457734 |
| acute myeloid leukemia | 0.996934 |
| acute myeloid leukaemia | 0.513022 |
| Leukemia Study Group | 0.464981 |
| juvenile myelomonocytic leukemia | 0.495899 |
| myeloid leukemia cells | 0.495298 |
| acute megakaryocytic leukemia | 0.484055 |
| mixed lineage leukemia | 0.460628 |
| Abstract | 0.599778 |
| Clin Oncol | 0.480965 |
| AML patients | 0.464901 |
| blood | 0.501248 |
| promyelocytic leukemia correlates | 0.463064 |
| acute promyelocytic leukemia | 0.625964 |
| pediatric AML | 0.496596 |
|
CLICK HERE |
| 1506 |
National Cancer Institute |
Html |
en |
Uterine Sarcoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of uterine sarcomas. |
| carcinosarcomas | 0.527692 |
| preceding study | 0.294778 |
| ongoing clinical trial | 0.328334 |
| higher response rate | 0.443879 |
| second-line therapy | 0.320988 |
| GOG-87B trial | 0.302772 |
| combination arm | 0.302761 |
| parallel endometrial cancer | 0.512209 |
| antitumor activity | 0.3101 |
| overall survival | 0.306973 |
| wrong pathology | 0.309304 |
| randomized comparison | 0.315064 |
| combination | 0.391895 |
| GOG-108 trial | 0.299664 |
| patients | 0.983458 |
| response rate | 0.846539 |
| toxic 5-day regimen | 0.481752 |
| epidemiologic features | 0.339925 |
| recurrent disease | 0.339729 |
| endometrial stromal cell | 0.349768 |
| homologous elements | 0.328462 |
| Gynecologic Oncology Group | 0.655599 |
| stromal components | 0.337885 |
| prior radiation therapy | 0.439727 |
| radiation therapy | 0.469225 |
|
| evaluable patients | 0.303784 |
| vs | 0.355238 |
| study | 0.345019 |
| postmenopausal predominance | 0.341262 |
| longer progression-free survival | 0.464996 |
| heterologous elements | 0.32327 |
| Carcinosarcomas parallel endometrial | 0.494212 |
| stromal cell sarcomas | 0.343743 |
| endometrial adenocarcinomas | 0.337476 |
| separate trials | 0.29781 |
| cisplatin | 0.316026 |
| first-line therapy | 0.436639 |
| significant improvement | 0.309111 |
| uterine sarcoma | 0.513207 |
| therapy | 0.475954 |
| follow-up GOG-0161 | 0.313043 |
| response rates | 0.291195 |
| chemotherapy studies | 0.29709 |
| modality approaches | 0.330804 |
| partial response rate | 0.446598 |
| uterine sarcomas | 0.312583 |
| hazard ratio | 0.311967 |
| confidence interval | 0.314154 |
| striated muscle | 0.341592 |
|
CLICK HERE |
| 1745 |
National Cancer Institute |
Html |
en |
Radon and Cancer |
A fact sheet about radon, an odorless radioactive gas, and its possible association with cancer, and how to test for radon in the home. |
| residential radon | 0.562353 |
| American case-control studies | 0.256996 |
| lung cancer | 0.983232 |
| radon test kit | 0.445489 |
| homes | 0.263005 |
| tiny radioactive particles | 0.260576 |
| radon risk | 0.437726 |
| indoor radon levels | 0.492199 |
| Lubin JH | 0.260179 |
| lung tumors | 0.286182 |
| long-term tests | 0.254643 |
| residential radon exposure | 0.479323 |
| average radon level | 0.4525 |
| slightly increased risk | 0.263122 |
| experimental animal studies | 0.260434 |
| radon gas | 0.490329 |
| radon programs | 0.421637 |
| radon exposure | 0.485254 |
| Environmental Protection Agency | 0.303434 |
| National Radon Hotline | 0.443169 |
| Radon Reduction | 0.421521 |
| radon testing | 0.473889 |
| radon | 0.847228 |
| National Radon | 0.44518 |
|
| United States | 0.325125 |
| radon causes lung | 0.520748 |
| radioactive gas | 0.261736 |
| high radon levels | 0.476793 |
| U.S. Environmental Protection | 0.30233 |
| underground uranium miners | 0.261056 |
| radon mitigation promotion | 0.443958 |
| normal decay | 0.26025 |
| low levels outdoors | 0.269932 |
| radon studies | 0.441219 |
| highest radon levels | 0.486865 |
| German uranium miners | 0.256763 |
| different indoor radon | 0.45539 |
| radioactive particles | 0.292648 |
| radon levels | 0.737469 |
| Health Physics | 0.256943 |
| Radon Program Services | 0.446453 |
| radon-related cancer deaths | 0.313801 |
| lung cancer deaths | 0.435124 |
| lung cancer risk | 0.337519 |
| local radon official | 0.450897 |
| elements uranium | 0.296591 |
| National Radon Hotlines | 0.444919 |
| et al | 0.254717 |
|
CLICK HERE |
| 1872 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de células de transición de pelvis renal y de uréter (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de células de transición de pelvis renal y de uréter. |
| Compton CC | 0.310067 |
| prognostic factors | 0.311079 |
| Roth BJ | 0.353197 |
| transitional cell carcinoma | 0.558604 |
| Sin embargo | 0.332107 |
| Ta Carcinoma | 0.313126 |
| Elson PJ | 0.309122 |
| California Oncology Group | 0.314515 |
| 7th ed | 0.310032 |
| tumores renales | 0.309511 |
| pelvis renal | 0.960657 |
| Instituto Nacional | 0.312591 |
| metástasis distantes | 0.32208 |
| células transicionales recidivantes | 0.361913 |
| pared pélvica renal | 0.316324 |
| parénquima renal t3 | 0.317938 |
| cooperative group study | 0.316918 |
| Cooperative Oncology Group | 0.315511 |
| tejido renal | 0.313083 |
| metastatic transitional cell | 0.319135 |
| preliminary report from | 0.31524 |
| group study | 0.325781 |
| Einhorn LH | 0.327583 |
| urinary tract | 0.331593 |
| función renal | 0.325386 |
|
| Northern California Oncology | 0.31495 |
| upper urinary tract | 0.318654 |
| effective chemotherapy regimen | 0.317306 |
| Oncology Group study | 0.317114 |
| Nocks BN | 0.30983 |
| Cancer Staging Manual | 0.321607 |
| PDQ Tratamiento | 0.309071 |
| Renal pelvic tumors | 0.315825 |
| New York | 0.30907 |
| Daly JJ | 0.308968 |
| with paclitaxel | 0.310585 |
| Clin Oncol | 0.437926 |
| parénquima renal | 0.327814 |
| Byrd DR | 0.309554 |
| urothelial carcinoma | 0.398878 |
| gallium combination chemotherapy | 0.316792 |
| insuficiencia renal | 0.313531 |
| Eastern Cooperative Oncology | 0.315974 |
| renal pelvis | 0.422209 |
| Oncology Group | 0.324511 |
| Tis Carcinoma | 0.313191 |
| metastatic urothelial carcinoma | 0.363244 |
| AJCC Cancer Staging | 0.322547 |
| Edge SB | 0.31008 |
|
CLICK HERE |
| 1962 |
National Cancer Institute |
Html |
es |
Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocíticas crónicas o juveniles, y la LMC atípica. |
| siguientes procedimientos | 0.310473 |
| células madre | 0.796441 |
| cuidado médico | 0.302013 |
| leucemia aguda | 0.308416 |
| células madre formadoras | 0.309431 |
| hueso compacto | 0.314757 |
| enlace drugs approved | 0.312251 |
| cromosoma filadelfia | 0.309322 |
| célula madre mieloide | 0.313237 |
| células anormales.ampliar aspiración | 0.315092 |
| National Cancer Institute | 0.302184 |
| siguientes riesgos | 0.301804 |
| leucemia mielomonocÃtica | 0.520866 |
| Instituto Nacional | 0.307834 |
| célula madre linfoide | 0.331173 |
|
| PDQ Tratamiento | 0.305968 |
| neurofibromatosis tipo | 0.303576 |
| células madre mieloide | 0.322767 |
| leucemia mielógena | 0.392932 |
| neoplasias mielodisplásicas | 0.970229 |
| Physician Data Query | 0.30823 |
| neoplasia mielodisplásica | 0.36973 |
| Myeloproliferative Neoplasms | 0.306895 |
| siguientes enlaces | 0.302219 |
| célula madre | 0.398378 |
| células sanguÃneas maduras | 0.374442 |
| neoplasias mieloproliferativas | 0.31703 |
| ósea elabora células | 0.32181 |
| siguientes pruebas | 0.312083 |
| siguientes sumarios | 0.307642 |
|
CLICK HERE |
| 3431 |
National Cancer Institute |
Html |
es |
Dietilestilbestrol (DES) y el cáncer |
Hoja informativa sobre el DES (una versión sintética del estrógeno) y los problemas de salud en los niños que estuvieron expuestos al DES en la matriz. |
| hormona femenina estrógeno | 0.312636 |
| Hatch EE | 0.454515 |
| DES problemas | 0.383286 |
| Urogenital abnormalities | 0.305699 |
| Diethylstilbestrol contraindicated | 0.311242 |
| exposed to diethylstilbestrol | 0.406175 |
| Cell Cancer Registry | 0.312383 |
| British Journal | 0.315496 |
| defectos congénitos | 0.317789 |
| reproductive characteristics | 0.305946 |
| Noller KL | 0.315866 |
| related synthetic hormones | 0.309521 |
| Prenatal diethylstilbestrol | 0.312976 |
| diethylstilbestrol during pregnancy | 0.315088 |
| Environmental Health | 0.313238 |
| posibles efectos | 0.334954 |
| Internal Medicine | 0.305939 |
| Estados Unidos | 0.328505 |
| DES Follow-up Study | 0.443119 |
| abortos espontáneos | 0.319323 |
| NCI MamografÃas | 0.30661 |
| resultados contradictorios | 0.314367 |
| long-term health effects | 0.309445 |
| PubMed Abstract | 0.959102 |
| International Journal | 0.31496 |
|
| Cancer Control | 0.307472 |
| Carcinogénesis Hormonal Transplacentaria | 0.310163 |
| DES daughters | 0.375119 |
| given diethylstilbestrol | 0.321239 |
| cohort study | 0.315559 |
| Titus-Ernstoff L | 0.382214 |
| Hormonal Transplacental Carcinogenesis | 0.31001 |
| mayores riesgos | 0.313929 |
| Environmental Health Sciences | 0.309128 |
| Troisi R | 0.359524 |
| Hoover RN | 0.313827 |
| stilbestrol therapy with | 0.308895 |
| FDA Drug Bulletin | 0.308403 |
| to diethylstilbestrol alters | 0.318831 |
| Verloop J | 0.312608 |
| cuello uterino | 0.526442 |
| Public Relations Committee | 0.308493 |
| exposed prenatally | 0.313265 |
| to des | 0.379155 |
| riesgos instantáneos porcentaje | 0.310067 |
| menopausia prematura | 0.316803 |
| to diethylstilbestrol | 0.546373 |
| New England Journal | 0.327355 |
| DES Porcentaje | 0.382487 |
|
CLICK HERE |
| 3451 |
National Cancer Institute |
Html |
en |
Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®)–Patient Version |
Expert-reviewed information summary about the preparation needed by health care providers, patients, and families for the transition to end-of-life care in advanced cancer. |
| CPR | 0.551685 |
| end-of-life decisions | 0.505947 |
| treatments | 0.539675 |
| PDQ cancer information | 0.625539 |
| Out-of-hospital DNR order | 0.511763 |
| health care team | 0.497649 |
| clinical trials | 0.511926 |
| wishes | 0.516111 |
| health care providers | 0.549541 |
| emergency medical workers | 0.548212 |
| cancer information summary | 0.569329 |
| health care professionals | 0.505787 |
| family members | 0.526957 |
| patients | 0.489953 |
| end-of-life care options | 0.519094 |
| symptoms | 0.496271 |
| NCI PDQ cancer | 0.514682 |
| new chemotherapy treatment | 0.48923 |
| doctors | 0.602249 |
| supportive care | 0.525701 |
| life-saving procedures | 0.497748 |
| care | 0.924816 |
| end-of-life care | 0.782032 |
| treatment | 0.671878 |
|
| DNR order | 0.576468 |
| Palliative Care Organization | 0.500652 |
| breathing stops | 0.496404 |
| palliative care | 0.693314 |
| Cancer Information Service | 0.494158 |
| Health care proxy | 0.49362 |
| cardiopulmonary resuscitation | 0.54384 |
| hospice care | 0.526131 |
| National Cancer Institute | 0.571506 |
| decisions | 0.647069 |
| Advance directives | 0.611485 |
| health care | 0.652677 |
| Palliative Care Editorial | 0.541845 |
| advanced cancer | 0.542943 |
| Cancer Care page | 0.510244 |
| Care Editorial Board | 0.540113 |
| PDQ summary | 0.57393 |
| doctor | 0.567646 |
| end stages | 0.495403 |
| breathing machine | 0.491509 |
| cancer information summaries | 0.492454 |
| comprehensive cancer information | 0.492895 |
| cancer | 0.776389 |
| information | 0.649786 |
|
CLICK HERE |
| 3526 |
National Cancer Institute |
Html |
es |
Dosis altas de vitamina C (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de dosis altas de vitamina C como tratamiento para personas con cáncer. |
| cuerpo capta | 0.40884 |
| Centro Nacional | 0.415435 |
| trastornos renales | 0.409265 |
| New Hampshire Avenue | 0.4108 |
| voluntarios sanos | 0.40968 |
| Drug Administration | 0.406678 |
| NCI Best Case | 0.417317 |
| vÃa oral | 0.410816 |
| datos bibliográficos pubmed | 0.411428 |
| Ewan Cameron | 0.409689 |
| siguientes preguntas | 0.406272 |
| modelo murino | 0.409716 |
| PDQ Dosis | 0.435611 |
| quÃmico linus pauling | 0.417313 |
| vitamina c | 0.94266 |
| National Cancer Institute | 0.412764 |
| siguientes riesgos | 0.407804 |
| Instituto Nacional | 0.459849 |
| quimio terapia | 0.40979 |
|
| premio nobel | 0.409373 |
| Salud Complementaria | 0.42125 |
| medicamento bortezomib | 0.415099 |
| Visuals Online | 0.407849 |
| complementarias revisa | 0.410331 |
| pequeñas cantidades | 0.408757 |
| Physician Data Query | 0.445061 |
| Estados Unidos | 0.504589 |
| cálculos renales | 0.409375 |
| libre uso | 0.407317 |
| cabo estudios | 0.435571 |
| claro cuánto | 0.409653 |
| página manejo | 0.407381 |
| ¿El tratamiento | 0.414934 |
| ¿Los beneficios | 0.406643 |
| juntos cam | 0.406416 |
| Series Program | 0.406643 |
| medicina complementaria | 0.607291 |
|
CLICK HERE |
| 3606 |
National Cancer Institute |
Html |
en |
Bioinformatics and Cancer |
Researchers take on challenges and opportunities to mine |
| analytical tools | 0.503896 |
| data | 0.930485 |
| complex biological questions | 0.5412 |
| computational tools | 0.425959 |
| research | 0.765612 |
| research program | 0.461031 |
| precision medicine—that | 0.427901 |
| Cancer Informatics Program | 0.53792 |
| primary data | 0.493101 |
| research community | 0.640856 |
| comprehensive molecular analyses | 0.497733 |
| cancer research data | 0.639487 |
| researchers | 0.498144 |
| molecular characteristics | 0.432662 |
| Big Data | 0.513141 |
| NCI’s Center | 0.486223 |
| NCI-funded studies | 0.438225 |
| NCIP Hub | 0.491716 |
| commercial cloud providers | 0.498944 |
| cloud technology | 0.483618 |
| Genome Research Institute | 0.551547 |
| cancer research community | 0.589113 |
| access | 0.431106 |
| numerous research areas | 0.554113 |
| imaging studies | 0.432684 |
|
| NCI-funded research | 0.466881 |
| cancer research | 0.762444 |
| healthy tissue samples | 0.490086 |
| data clouds | 0.491108 |
| NCI’s TARGET | 0.476821 |
| TCGA-collected data | 0.483444 |
| Genomic Data Sharing | 0.579305 |
| molecular data | 0.478795 |
| multi-investigator research teams | 0.550054 |
| different technological platforms | 0.513272 |
| studies | 0.49641 |
| translational studies | 0.42911 |
| sheer volume | 0.427853 |
| NCI Cancer Genomics | 0.60107 |
| cancer researchers | 0.462047 |
| cancer genomics repository | 0.530232 |
| biological data | 0.643746 |
| clinical care | 0.431785 |
| different tools | 0.428018 |
| Cancer Genome Atlas | 0.527253 |
| biomedical research | 0.47962 |
| cancer research projects | 0.699979 |
| potential new targets | 0.495536 |
| NCI Genomic Data | 0.63374 |
|
CLICK HERE |